RxDoctor Payments DataLook up a doctor →

Irtza Sharif, MD

Critical Care Medicine · Kissimmee, FLNPI 1689803454

Payments from drug & device makers

$44,359in general payments, 2019–2025

Across 577 payments — averaging $76.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$14K
  • Actelion Pharmaceuticals, Ltd$7K
  • Pinnacle Biologics, Inc$3K
  • AstraZeneca$3K
  • Johnson & Johnson$3K
  • GSK$3K
  • plus $11K from 44 others

What the payments were for

  • Speaking & faculty fees$7503%
  • Travel & lodging$3,28414%
  • Food & beverage$19,31882%
  • Education$1561%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$44,359 in reported general payments places this provider in the 90th percentile of 618 critical care medicine providers in Florida.

See all critical care medicine providers in Florida

Medicare billing

Part B allowed, 2024
$79,436
Medicare patients
205
Services billed
1,408

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate25$327,138
Trelegy ElliptaFluticasone/Umeclidin/Vilanter306$255,101
HizentraImmun Glob G(Igg)/Pro/Iga 0-5015$125,731
Breztri AerosphereBudesonide/Glycopyr/Formoterol89$59,064
EliquisApixaban48$41,204
Stiolto RespimatTiotropium Br/Olodaterol Hcl25$13,873
SymbicortBudesonide/Formoterol Fumarate34$11,019
Breo ElliptaFluticasone/Vilanterol22$9,219
Spiriva RespimatTiotropium Bromide12$7,118
Fluticasone-SalmeterolFluticasone Propion/Salmeterol18$3,633
Albuterol Sulfate HfaAlbuterol Sulfate165$3,545
Ventolin HfaAlbuterol Sulfate14$786
Montelukast Sodium73$719
Azithromycin18$371
Fluticasone Propionate12$218

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat$2,133$348,13062 claims
GSKTrelegy Ellipta, Breo Ellipta$2,564$264,320328 claims
AstraZenecaBreztri Aerosphere, Symbicort$3,137$70,082123 claims
PfizerEliquis$54$41,20448 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 618 critical care medicine providers in Florida.

Other critical care medicine in Kissimmee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →